search
Back to results

DeteCtiON and Stroke PreventIon by MoDEl ScRreenING for Atrial Fibrillation (CONSIDERING-AF)

Primary Purpose

Atrial Fibrillation, Atrial Flutter

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Risk prediction model
14-days continuous ECG monitoring
Sponsored by
Bristol-Myers Squibb
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Atrial Fibrillation focused on measuring Atrial Fibrillation, Atrial Flutter, Mass Screening

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Alive residents in the Halland region aged 65 or older without a recorded diagnosis of AF Exclusion Criteria: Known atrial fibrillation Death No longer resident in Region Halland Pacemaker, implantable cardioverter defibrillator or insertable monitor Dementia Other indication for OAC treatment (such as VTE, mechanical heart valve replacement, VTE prophylaxis post surgery, mitral stenosis, left side intracardial thrombus)

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    No Intervention

    Experimental

    Experimental

    Experimental

    Arm Label

    General/control

    General/intervention

    Risk prediction model/control

    Risk prediction model/intervention

    Arm Description

    Standard of care.

    Standard of care plus 14-days continuous ECG monitoring using an ECG patch.

    Standard of care.

    Standard of care plus 14-days continuous ECG monitoring using an ECG patch.

    Outcomes

    Primary Outcome Measures

    Incident AF
    Incident AF on ECG screening (intervention arms) defined as at least one episode of AF or atrial flutter with a duration of at least 30 seconds on ambulatory ECG recording. Incident AF registered in the Electronic Health Record during follow-up (all four arms).

    Secondary Outcome Measures

    Yield newly diagnosed AF: RPM/ intervention arm versus RPM/ control arm
    To compare the yield of newly diagnosed AF using 14-days continuous ECG in a population aged ≥ 65 years with an increased risk for AF incidence according to the RPM compared with a population with increased risk according to the RPM without intervention.
    Yield newly diagnosed AF: general/ intervention arm versus RPM/ control arm
    To compare the yield of newly diagnosed AF using 14-days continuous ECG in a general population aged ≥ 65 years compared with a population with increased risk according to the RPM without intervention.
    Yield newly diagnosed AF: general/ intervention arm versus general/ control arm
    To compare the yield of newly diagnosed AF using 14-days continuous ECG in a general population aged ≥ 65 years compared with a general population without intervention.
    Proportion of patients starting oral anticoagulation treatment
    Proportion of patients starting oral anticoagulation treatment among those newly diagnosed with AF in both general and RPM arms.

    Full Information

    First Posted
    April 20, 2023
    Last Updated
    April 20, 2023
    Sponsor
    Bristol-Myers Squibb
    Collaborators
    Region Halland, Halmstad University, Karolinska Institutet, Pfizer, Philips Healthcare
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05838781
    Brief Title
    DeteCtiON and Stroke PreventIon by MoDEl ScRreenING for Atrial Fibrillation
    Acronym
    CONSIDERING-AF
    Official Title
    DeteCtiON and Stroke PreventIon by MoDEl ScRreenING for Atrial Fibrillation
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    August 14, 2023 (Anticipated)
    Primary Completion Date
    February 14, 2024 (Anticipated)
    Study Completion Date
    December 31, 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Bristol-Myers Squibb
    Collaborators
    Region Halland, Halmstad University, Karolinska Institutet, Pfizer, Philips Healthcare

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Atrial fibrillation (AF) is the most common clinical arrhythmia and the prevalence increases with age. AF increases the risk of ischaemic stroke fivefold and accounts for almost one-third of all strokes. As AF is often asymptomatic there are many undetected cases. It is important to find patients with AF and additional risk factors for stroke in order to initiate oral anticoagulation treatment, which can reduce the risk of an ischaemic stroke by 60-70%. Screening is recommended in European guidelines, however the most suitable population and the most suitable device for AF detection remain to be defined. The main objective of this study is to test the hypothesis that AF screening with 14-days continuous ECG monitoring in high-risk individuals identified with a risk prediction model is more effective than routine care in identifying patients with undetected AF. Effectively detecting AF among patients with risk factors for ischaemic stroke has the potential to decrease mortality and morbidity, stroke burden and costs for the society as a whole.
    Detailed Description
    Objective(s): To compare the yield of atrial fibrillation (AF) using 14-days continuous ECG in a population aged ≥ 65 years with an increased risk for AF incidence according to the risk prediction model compared with standard of care in Region Halland. Study Population: Residents in Region Halland age 65 and above. Data Collection Methods: Electronic Health Records from Region Halland and 14-days continuous ECG recording using an ECG patch. Study design: Step 1: To calibrate the BMS/Pfizer risk prediction model (RPM), we will extract two cohorts retrospectively: the AF cohort with an AF diagnosis (patients with a record of incident AF diagnosis between January 1, 2016, and December 31, 2019 as an observation period), and the control cohort without any AF diagnosis in their history. We will include patients ≥45 years of age at index date, which is the first date of an AF diagnosis recorded in the observation period and a random pseudo index date during the observation period for the control group, to follow the original study. Specifically, we are looking to calibrate the intercept (α) for the logistic regression where we already have the 13 odd ratios for the 13 risk factors from the original study. Then in the next step for the prospective study, applying the RPM on the RPM cohort, the at-risk group will be extracted for randomization step, using the recommended cut-off value. Step 2: The population in Region Halland aged 65 years and above and free from AF will be randomized into two halves, creating a general cohort and an RPM cohort. In the general cohort, 1480 individuals will be further randomized into two arms, general/control and general/intervention. In the RPM cohort, the risk of incident AF will be calculated according to the Pfizer/BMS RPM. Those with a predicted risk for incident AF above a pre-specified threshold will then be randomly extracted into two arms, RPM/control and RPM/intervention (figure 1). Those randomized to the two intervention arms (general/intervention and RPM/intervention, n=740 each) will be invited to an AF screening intervention of 14-days continuous ECG using a patch device. Those randomized to the control groups (general/control and RPM/control, n=740 each) will not receive any information or intervention. The primary endpoint will be the difference in yield of newly diagnosed AF between the RPM/intervention and the general/control arms, where the latter will represent standard of care. Participants with newly diagnosed AF in the intervention arms will be offered consultation aiming at AF work-up and initiation of oral anticoagulation treatment.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Atrial Fibrillation, Atrial Flutter
    Keywords
    Atrial Fibrillation, Atrial Flutter, Mass Screening

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Factorial Assignment
    Model Description
    Siteless, randomized, 2x2 factorial design, superiority trial
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    2960 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    General/control
    Arm Type
    No Intervention
    Arm Description
    Standard of care.
    Arm Title
    General/intervention
    Arm Type
    Experimental
    Arm Description
    Standard of care plus 14-days continuous ECG monitoring using an ECG patch.
    Arm Title
    Risk prediction model/control
    Arm Type
    Experimental
    Arm Description
    Standard of care.
    Arm Title
    Risk prediction model/intervention
    Arm Type
    Experimental
    Arm Description
    Standard of care plus 14-days continuous ECG monitoring using an ECG patch.
    Intervention Type
    Diagnostic Test
    Intervention Name(s)
    Risk prediction model
    Intervention Description
    A risk prediction model (RPM) based on logistic regression. The RPM uses 13 variables accessible in healthcare registers to identify individuals with high future risk for developing AF. ICD-10 codes will be used.
    Intervention Type
    Diagnostic Test
    Intervention Name(s)
    14-days continuous ECG monitoring
    Intervention Description
    14-days continuous ECG monitoring with an ECG patch.
    Primary Outcome Measure Information:
    Title
    Incident AF
    Description
    Incident AF on ECG screening (intervention arms) defined as at least one episode of AF or atrial flutter with a duration of at least 30 seconds on ambulatory ECG recording. Incident AF registered in the Electronic Health Record during follow-up (all four arms).
    Time Frame
    14 days
    Secondary Outcome Measure Information:
    Title
    Yield newly diagnosed AF: RPM/ intervention arm versus RPM/ control arm
    Description
    To compare the yield of newly diagnosed AF using 14-days continuous ECG in a population aged ≥ 65 years with an increased risk for AF incidence according to the RPM compared with a population with increased risk according to the RPM without intervention.
    Time Frame
    14 days
    Title
    Yield newly diagnosed AF: general/ intervention arm versus RPM/ control arm
    Description
    To compare the yield of newly diagnosed AF using 14-days continuous ECG in a general population aged ≥ 65 years compared with a population with increased risk according to the RPM without intervention.
    Time Frame
    14 days
    Title
    Yield newly diagnosed AF: general/ intervention arm versus general/ control arm
    Description
    To compare the yield of newly diagnosed AF using 14-days continuous ECG in a general population aged ≥ 65 years compared with a general population without intervention.
    Time Frame
    14 days
    Title
    Proportion of patients starting oral anticoagulation treatment
    Description
    Proportion of patients starting oral anticoagulation treatment among those newly diagnosed with AF in both general and RPM arms.
    Time Frame
    14 days
    Other Pre-specified Outcome Measures:
    Title
    Cost-effective analysis
    Description
    Cost-effectiveness analysis of the risk prediction model together with the ECG patch compared to standard care. The possibility to increase survival as a consequence of avoiding AF-related events will then be compared to increased screening costs as well as cost of treatment.
    Time Frame
    14 days
    Title
    Feasibility of self-application of ECG patch
    Description
    To study uptake and feasibility of self-application of ECG patch.
    Time Frame
    14 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Alive residents in the Halland region aged 65 or older without a recorded diagnosis of AF Exclusion Criteria: Known atrial fibrillation Death No longer resident in Region Halland Pacemaker, implantable cardioverter defibrillator or insertable monitor Dementia Other indication for OAC treatment (such as VTE, mechanical heart valve replacement, VTE prophylaxis post surgery, mitral stenosis, left side intracardial thrombus)
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Johan Engdahl, MD, PhD
    Phone
    +46737593374
    Email
    johan.engdahl@regionstockholm.se
    First Name & Middle Initial & Last Name or Official Title & Degree
    Emma Sandgren, MD, PhD
    Phone
    +46722245555
    Email
    emma.sandgren@regionhalland.se
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Johan Engdahl, MD, PhD
    Organizational Affiliation
    Karolinska Institutet
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    DeteCtiON and Stroke PreventIon by MoDEl ScRreenING for Atrial Fibrillation

    We'll reach out to this number within 24 hrs